Healthcare Industry News: Aricept
News Release - April 22, 2010
pHase Pharmaceuticals Announces New VentureDALLAS, April 22 -- (Healthcare Sales & Marketing Network) -- pHase Pharmaceuticals, LLC announces the launch of its new drug development company. pHase Pharmaceuticals is led by a cohesive team of drug development experts who have extensive experience bringing new drugs to market and garnering FDA approval.
Having developed numerous commercially successful new drugs, the pHase team has now identified an unmet clinical need in a large and growing market. The principals of pHase have already invested significant capital to initiate the development of a superior form of delivery for a drug in the allergy/immunology space that offers significant clinical, cost and ease of use advantages over the current form of treatment. In addition, the team has identified and confirmed a streamlined regulatory path that accelerates time to market while decreasing development costs.
The team consists of Dr. Lynn Yohana Howard, Dr. Nicholas Farina, Edward Walters and Chris Howard. Members of this team were instrumental in the development of such blockbuster drugs as Aricept, Aciphex, Altocor/Altoprev, Fortamet and Sodium Valproate. The teams extensive experience in both the formulation of new compounds along with the management of the manufacturing process, clinical trials and FDA approvals, particularly 505 b(2), positions them to succeed in this new venture.
pHase is currently in the process of securing additional capital to fund the 2nd phase of their initial drug development project. Further information on the team can be found on the company's website www.phasepharma.com.
Carillon Capital Partners is serving as an advisor to pHase and is leading the current effort to raise growth capital for the company. Carillon Capital Partners is a boutique investment bank, strategic advisor and merchant bank specializing in helping a broad range of companies in the financial services, healthcare, technology and defense industries. For further information, please see www.carilloncapital.com.
Source: Carillon Capital Partners
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.